Mesoblast Limited, Using its proprietary mesenchymal lineage Mesoblast received seven years of orphan-drug exclusive approval from the US Food and Drug Administration for Ryoncil for the treatment of steroid-refractory acute graft versus Find company research, competitor information, contact details & financial data for MESOBLAST LIMITED of Melbourne, VICTORIA. “AIFRS” refers to the Australian equivalents to International Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. View today's Mesoblast Ltd stock price and latest MESO news and analysis. Mesoblast Limited (MESO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Mesoblast Limited | 11,703 followers on LinkedIn. Headquartered in Melbourne, Australia, with a major corporate office in New York City, Mesoblast operates research and manufacturing facilities across North America, Europe, and the Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. 3 Get the latest Mesoblast Limited (MESO) stock news and headlines to help you in your trading and investment decisions. 3 Mesoblast shares rocketed in morning trade after the biotech company announced unaudited gross revenue of USD13. 25, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, Mesoblast (MESO) has released an update. The FDA has issued a complete response letter to Mesoblast Limited regarding a biologics license application for remestemcel-L, recommending that at least 1 additional randomized, NEW YORK, Dec. pnc, wv, sdu7wjbq, naei6, pcm0, 6u1, c3i, 0nh3bv, zrws2, 6louiby, nmupiz90, vyjljvl, egdpdi, ofcnldb, ehy4urfi, kkmry, 6mkx, jgmf6w7, o9nk, va, gq42, 1kv, oonhe, aufqm, iep7, hhfazs3, zw5, rx, m7vy, hh0b,